Precision Medicine in Action: Launching Pharmacogenomics & Nutrigenomics in RSU Royal Prima, Medan
Medan, North Sumatra, Indonesia
In Collaboration with RSU Royal Prima Medan
- Prof. Dr. Tommy Leonard, SH, M.Kn., President Director, PT Royal Prima, Tbk
- Dr. dr. Wienaldi, MKM, MQM, President Director, RSU Royal Prima
- Ridyawati, S.Ak, MM, General Manager, RSU Royal Prima
- Indrida Rahmi, SH, M.Kn., Corporate Secretary & Legal Officer, PT Royal Prima, Tbk
- Dr. Rebecca Tay, CEO, Global Precision Diagnostics
- Dr. Gew Soon Peng, COO, Global Precision Diagnostics
- Ms. Maria Phang, Operations Director, Global Precision Diagnostics
- Ms. Nanny Sukimin, CEO, Medis Online & Regional Account Lead, Global Precision Diagnostics
- Along with other distinguished guests and clinicians
The health landscape of Medan
With the introduction of Pharmacogenomics testing, patients in Medan can now receive:
● Genetic information to personalize medication choices
● Reduced risk of adverse drug reactions
● More precise, evidence-based care
Our Nutrigenomics testing further enables individuals to make informed decisions on nutrition, supplementation, and lifestyle, based on their unique genetic profile.
This partnership reflects a shared vision to transform diagnostics and preventive care across Indonesia, bringing us one step closer to a future where healthcare is more precise, predictive, and patient-centric.
We sincerely thank RSU Royal Prima, UNPRI, and all stakeholders who helped make this launch a success. Together, we are shaping the future of personalized healthcare, powered by science and grounded in compassion. It was also a true honour to visit Universitas Prime Indonesia (UNPRI), one of Sumatra’s top universities, and to witness their strong leadership and commitment to clinically accredited, patient-first solutions.
We’re humbled to share that Precision Diagnostics 𝐡𝐚𝐬 𝐛𝐞𝐞𝐧 𝐫𝐞𝐜𝐨𝐠𝐧𝐢𝐳𝐞𝐝 𝐚𝐬 𝐚 𝐜𝐨𝐦𝐩𝐚𝐧𝐲 𝐮𝐧𝐝𝐞𝐫 𝐁𝐢𝐨-𝐛𝐚𝐬𝐞𝐝 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐨𝐫 𝐏𝐫𝐨𝐠𝐫𝐚𝐦 𝐮𝐧𝐝𝐞𝐫 𝐁𝐢𝐨𝐞𝐜𝐨𝐧𝐨𝐦𝐲 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐢𝐨𝐧, and has also been officially recognised by the Malaysia Book of Records for:
🏆 𝟏ˢᵗ 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐑𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐞𝐝 𝐆𝐞𝐧𝐨𝐦𝐞-𝐖𝐢𝐝𝐞 𝐏𝐆𝐱 (2023)
🏆 𝐋𝐚𝐫𝐠𝐞𝐬𝐭 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐀𝐜𝐜𝐫𝐞𝐝𝐢𝐭𝐞𝐝 𝐏𝐆𝐱 𝐂𝐚𝐦𝐩𝐚𝐢𝐠𝐧 (2025, with Sunway Multicare Group)
Thank you to RSU Royal Prima, UNPRI, and all collaborators who made this possible. Together, we are shaping a future of healthcare that is precise, predictive, and personal.
About Precision Diagnostics
Precision Diagnostics is a Malaysia-based leader in genetic testing, specializing in pharmacogenomics (PGx) and nutrigenomics (NGx). We provide personalized healthcare solutions across 20+ therapeutic areas, including oncology and cardiovascular health. We adhere to international standards set by leading bodies such as the FDA, HSA (Singapore), CPIC, DPWG, IWPC, and NCCN.
